Evaluation of costs, osteoporosis treatment, and re-fractures in German collaborative orthogeriatric care after fragility fractures
Authors' conclusion
The observed healthcare costs were higher in ATZ and OGCM hospitals within 12 months. Antiosteoporotic medication was prescribed more often in both groups for most fracture sites, although the corresponding medication costs did not increase.
Study context
- Population
- Individuals aged 80 years and older with a fragility fracture in 2014–2018, German health and long-term care insurance data12-month follow-up
- Participants
- 206,273 individuals
- Exposure
- Hospitals certified for orthogeriatric co-management (OGCM) (ATZ) and hospitals providing OGCM without certification (OGCM) vs usual care
- ATZn = 14,100
- OGCMn = 133,353
- Controln = 58,820reference
- Outcome
- Healthcare costs from payer perspective, prescribed medications and re-fractures
- Follow-up
- 6 and 12 months
Methodological detailsentropy balancing, weighted gamma and two-part models, stratified per fracture site
- Entropy balancing
- Weighted gamma and two-part models
- Stratified per fracture site
Main finding
As reported in the abstract
Total average inpatient costs per patient · 12 months
- Significantly higher in the OGCM and particularly ATZ group for all fracture sites, compared to control group
Observational data: associations, not effects.
Further findings
Costs for re-fractures or antiosteoporotic medication
- No significant differences for most fracture sites
Antiosteoporotic medication prescription
- Significantly more often in the OGCM and particularly ATZ group for hip, pelvic and humerus fractures
Original publication
Evaluation of costs, osteoporosis treatment, and re-fractures in German collaborative orthogeriatric care after fragility fractures. Osteoporos Int. Published 9 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →